BioNTech SE (BNTX)

Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Sec...

Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin...

Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Hum...

Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slowe...

BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. However, note that some regulatory and legal challenges, including a Moderna patent rul...

BioNTech SE (NASDAQ:BNTX ) Q4 2024 Earnings Conference Call March 10, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder and Chief Executive O...

U.S.-listed shares of BioNTech (BNTX) lost ground Monday, as the COVID-19 vaccine maker's soft outlook for the year offset better-than-expected quarterly results.

BioNTech SE  BNTX on Monday reported fourth-quarter per-share earnings of 1.08 euros ($1.17), down from 1.88 euros reported a year ago compared to the consensus of 38 cents.

Biopharmaceutical company BioNTech SE (BNTX -1.85%) reported fourth-quarter and full-year 2024 earnings on Monday, March 10, that topped analysts' consensus expectations. It reported revenue of 1.19 b...